Germany, FranceFrance

Micromet seals early stage deal for antibody with Sanofi


Bethesda/Munich/Paris - Micromet Inc. partnered with sanofi-aventis Group to develop one of the biotech's bispecific T cell engager (BiTE) antibodies for cancer. The Paris-based pharma will pay €8 million up front, and Micromet agreed to take on the discovery, research and development of an antibody targeting an undisclosed antigen found on carcinoma cells through the end of Phase I trials. Micromet gained (13%) on Thursday.
After that, Sanofi will take over, and Micromet will be eligible for up to €312 million in milestones - €162 million for development and regulatory achievements and €150 million for performance-based sales milestones - plus royalties on product sales. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks.
Piper Jaffray analyst Edward Tenthoff called it a "huge preclinical discovery deal," even larger than its January agreement with Berlin-based Bayer Schering AG, which paid €4.5 million for a one-year option to a preclinical BiTE antibody for cancer.Under the terms of that collaboration, Bayer has until Jan. 5, 2010, to license an antibody, at which time it will pay an option fee and put Micromet in the path of potential milestone payments of up to €290 million.
Micromet is nominally a US-company and listed at the American Stock Exchange but does all the research from Germany, where it was founded 1993 in Munich.



Minneapolis/Banzancourt – Bioamber Inc. is one step closer to the environmental summit. The company's goal is to establish sustainable, "green" chemistry on an industrial scale. The French/US enterprise has now scaled up its...



Sophia Antipolis/ Madison – French NicOx S.A. and the global eye health specialist Bausch & Lomb have announced positive top-line results from their phase 2b dose finding study with BOL-303259-X, a nitric oxide-donating version...



Paris/Barcelona – French pharma company Sanofi strengthens its ties with the Spanish research institution CGR (Center for Genomic Regulation) in Barcelona. CGR stated on 12 March that the two partners agreed upon three years of...



Lyon – The sale of 1.6 million shares brought in €25.3m for French Adocia SAS during its IPO on the Euronext Paris. The price of €15.88 values the diabetes specialist at €96.1m at the upper end of the bookbuilding range. Late...



Pointing to a new study on Syngenta’s GM maize Bt11, France’s Environment Ministry has asked the European Commission to suspend authorisation for the use of the MON810 maize sold by US agri­biotech giant Monsanto as well. The...



Cambridge - Genzyme will shut the doors at its Cambridge R&D site by the end of the year, with up to 60 employees expected to lose their jobs. The move is part of an ongoing global restructuring of R&D by Sanofi, who purchased...



Lille – Shares of the French diabetes specialist Genfit S.A. almost doubled when the company published results of its Phase II study with the PPAR alpha and delta modulator GFT505. The compound has met the co-primary and...



Shares of the French diabetes specialist almost doubled when the companypublished results of its Phase II study with the PPAR alpha and deltamodulator GFT505. The compound has met the co-primary and secondaryendpoints while...



Bagneux - DBV Technologies is planning an IPO on Euronext Paris. The French pharmaceutical group specialising in the treatment of allergies was founded in 2002. DBV's proprietary technology Viaskin is used to administer an...



Berlin/Paris – Sanofi Pasteur has licensed a yeast strain from German Organobalance to produce vaccines. With the deal, the vaccines division of the French drugmaker will gain exclusive access to a modified strain of...

Displaying results 1 to 10 out of 268

1-10 Next >

© 2007-2015 BIOCOM


All Events


Product of the week


Current issue

All issues